Sign in

You're signed outSign in or to get full access.

VI

Veradigm Inc. (MDRX)·Q4 2024 Earnings Summary

Executive Summary

  • Veradigm’s Q4 2024 investor update framed full-year FY 2024 preliminary unaudited results below prior guidance: GAAP revenue $583–$588M, GAAP net loss ($49)–($46)M, and Adjusted EBITDA $85–$90M; drivers were implementation delays in payer solutions, higher provider RCM attrition, and biopharma softness in life sciences .
  • 2025 outlook: revenue expected to be approximately flat vs 2024 and net cash to remain positive; management is pursuing additional debt financing ahead of a convertible notes put right on July 1, 2025 .
  • Company filed its comprehensive 2022 Form 10-K with restated financials and outlined remediation of material weaknesses; management expects becoming current on filings and completing remediation in 2026 .
  • Catalyst set-up: lowered FY 2024 vs prior guidance, explicit 2026 timeline to regain current filings, AI-enabled product roadmap, and capital structure updates (convertible notes put), all discussed on the Q4 call .

What Went Well and What Went Wrong

What Went Well

  • Signed notable provider wins in specialty markets (urology, largest U.S. wound care org) and expanded payer penetration (seven new Care Gap clients in last three months; 400 new sites onboarded in 2025 to date) .
  • Clear AI strategy across provider workflows, payer data exchange, and life sciences datasets; ScienceIO serves as AI center of excellence to drive product differentiation and operational efficiency .
  • Filed 2022 Form 10-K and detailed restatement findings and remediation plan; refreshed board and governance to support go-forward execution .

Selected quotes:

  • “We remain confident in Veradigm’s business model and our value proposition.” — Interim CEO Tom Langan .
  • “We believe the application of our in house generative AI capabilities will drive deeper insights and greater value for our clients.” — Tom Langan .

What Went Wrong

  • FY 2024 revenue fell short of prior guidance by ~$42M at midpoint; shortfall was concentrated in H2 with broader declines across segments (provider ~⅓; payer & life sciences ~⅔ of total shortfall) .
  • Higher-than-expected provider net attrition, particularly in revenue cycle management, and lower net new sales; Koa Health acquisition saw client attrition impacting 2024 .
  • Elevated “transaction and other” costs (audit, advisory, legal) drove cash outflows; net cash fell from $239M (2023) to $87M (2024) .

Financial Results

MetricFY 2023 (Estimated)FY 2024 (Estimated)
Revenues ($USD Millions)$620–$625 $583–$588
GAAP Net Income (Loss) ($USD Millions)$62–$65 ($49)–($46)
Adjusted EBITDA ($USD Millions)$139–$144 $85–$90
Adjusted EBITDA Margin %23%–24% 15%
Net Income Margin %10% -8%
EPS ($USD)Not disclosed Not disclosed

Segment Revenue Breakdown

SegmentFY 2023 Revenue GAAP ($USD Millions)FY 2024 Revenue GAAP ($USD Millions)YoY Change
Provider$490–$493 $466–$469 -1% (CFO commentary)
Payer & Life Science$130–$132 $117–$119 -10% (CFO commentary)
NoteFavorable customer settlements: $19M in 2023, $1M in 2024; all in Provider

KPIs

KPIFY 2023FY 2024
Net Cash ($USD Millions)$239 $87
Cash & Equivalents ($USD Millions)$447 $295
Funded Debt ($USD Millions)$208 $208
Recurring Revenue (% of Total)~80% ~80%

2024 Guidance vs Updated Estimates

Metric2024 Guidance (Mar 2024)2024 Est. (Mar 18, 2025)Variance
Revenue (GAAP, $USD Millions)$620–$635 $583–$588 ($37)–($47)
Adjusted EBITDA ($USD Millions)$104–$113 $85–$90 ($19)–($23)
GAAP Net Loss ($USD Millions)N/A ($49)–($46) N/A

Guidance Changes

MetricPeriodPrevious GuidanceCurrent Guidance/OutlookChange
Revenue (GAAP)FY 2024$620–$635M (Mar 13, 2024) $583–$588M (Mar 18, 2025) Lowered
Adjusted EBITDAFY 2024$104–$113M (Mar 13, 2024) $85–$90M (Mar 18, 2025) Lowered
Net CashFY 2024~positive (context) $87M as of Dec 31, 2024 Lower vs 2023
RevenueFY 2025N/AApproximately flat vs 2024 Maintained (flat)
Net CashFY 2025N/AExpected to remain positive Maintained (positive)
Capital Structure2025N/AConvertible notes put right on 07/01/2025; pursuing new debt financing New disclosure

Earnings Call Themes & Trends

TopicPrevious Mentions (Q-2 and Q-1)Current Period (Q4 2024)Trend
AI/technology initiativesIntroduced ScienceIO integration and proprietary LLM; 2024 investment year for AI-enabled data products AI enabling provider workflow automation, payer data access, and premium life sciences datasets; ScienceIO is AI center Ramping deployment across segments
Provider business/RCMNo prior quantified attrition disclosed; expected growth in 2024 Higher provider net attrition, particularly in RCM; Koa Health client attrition post-acquisition Headwind emerged in H2 2024
Payer implementationsGap Closure deployments highlighted in strategy Implementation and go-live delays in clinical data exchange and Gap Closure; seven new clients added Mixed: delays vs new wins
Life sciences demandAnticipated growth with AI-driven data; media and data offerings emphasized Industry-wide biopharma softness hit RWD and media bookings; early Q1 2025 signs of pickup Weakening in late 2024; improving early 2025
Regulatory/legal & filingsDelisting and prolonged audits noted; guidance contingent on audit work 2022 10-K filed; plan to become current and complete remediation in 2026 Progress, but extended timeline

Management Commentary

  • Strategy and positioning: “Veradigm is a leading healthcare data and intelligence organization uniquely positioned at the intersection of the three pillars of healthcare, payer, provider and life sciences…we believe that the application of our in house generative AI capabilities will drive deeper insights and greater value for our clients.” — Tom Langan .
  • Cost and margin outlook: “We are in the midst of a cost realignment…impact will be occurring in favorable impact on our margins during 2025 and a more significant impact…in 2026.” — Lee Westerfield .
  • Governance and remediation: “We have a refreshed Board…Yesterday, we reached an important milestone by filing our Form 10-Ks…This marks a crucial step in becoming current in our financial reporting.” — Tom Langan .
  • Confidence statement: “We remain confident in Veradigm’s business model and our value proposition.” — Tom Langan .

Q&A Highlights

  • Filings/remediation timeline: Both regaining current filings and completing remediations are expected in 2026, with audits of 2023–2025 and quarterlies to be sequenced; updates will be provided periodically .
  • Revenue shortfall drivers: H2 2024 shortfall due to payer implementation go-live delays and life sciences media/RWD softness; provider net new softness and higher RCM attrition also impacted .
  • Provider attrition details: Higher attrition in large physician practices (affiliations, consolidation), more stability in small/mid practices; Koa Health client attrition noted .
  • Capital structure/liquidity: Convertible note holders have a put right on 07/01/2025; management pursuing new debt financing despite net cash positive position to prudently support liquidity .
  • ScienceIO impact: No 2024 revenue from ScienceIO; combined Koa+ScienceIO mid-teens millions of expense in 2024; future $15M installments due Jan 2026 and Jan 2027 .

Estimates Context

  • Wall Street consensus estimates via S&P Global were unavailable for MDRX at the time of this analysis due to mapping constraints, so comparisons to consensus EPS and revenue for Q4 2024 and FY 2024 cannot be made.

Key Takeaways for Investors

  • FY 2024 undershot prior guidance, with weakness concentrated in H2 and skewed to payer and life sciences; watch for implementation timing and biopharma spending normalization to determine 2025 trajectory .
  • 2025 revenue set to be approximately flat with an emphasis on margin improvement from cost actions; monitor cadence of cost realignment and any quantified margin targets in future updates .
  • Liquidity remains positive net cash, but convertible notes put in July 2025 and pursuit of new debt financing introduce capital structure catalysts; track refinancing outcomes and any terms affecting flexibility .
  • AI initiatives are central to the product roadmap and differentiation across segments; execution milestones (provider workflow AI, payer data exchange, life sciences premium datasets) could support growth and mix shift over time .
  • Governance and remediation progress (2022 10-K filed; 2026 target for current status) reduces uncertainty but extends the timeline; expect periodic business updates rather than regular quarterly reporting until current .
  • Provider segment stability is stronger in small/mid markets; RCM attrition and Koa Health integration are execution priorities—new specialty wins are encouraging, but net attrition must moderate to support top line .
  • Near-term trading: headline risk around audit progress, guidance confirmations, and financing; medium-term thesis hinges on AI-enabled product adoption, payer implementations, and life sciences demand recovery, alongside margin expansion from cost actions .